Cargando…

Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

BACKGROUND: Women with node-positive vulvar cancer have a high risk for disease recurrence. Indication criteria for adjuvant radiotherapy are controversial. This study was designed to further understand the role of adjuvant therapy in node-positive disease. METHODS: Patients with primary squamous-ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahner, Sven, Jueckstock, Julia, Hilpert, Felix, Neuser, Petra, Harter, Philipp, de Gregorio, Nikolaus, Hasenburg, Annette, Sehouli, Jalid, Habermann, Annika, Hillemanns, Peter, Fuerst, Sophie, Strauss, Hans-Georg, Baumann, Klaus, Thiel, Falk, Mustea, Alexander, Meier, Werner, du Bois, Andreas, Griebel, Lis-Femke, Woelber, Linn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356703/ https://www.ncbi.nlm.nih.gov/pubmed/25618900 http://dx.doi.org/10.1093/jnci/dju426

Ejemplares similares

Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study
por: Woelber, Linn, et al.
Publicado: (2021)

Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?
por: Woelber, Linn, et al.
Publicado: (2020)

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
por: Woelber, Linn, et al.
Publicado: (2022)

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
por: Eulenburg, Christine, et al.
Publicado: (2016)

LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
por: Wanka, Giulia, et al.
Publicado: (2020)

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study
por: Trillsch, F, et al.
Publicado: (2015)

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
por: Emons, Günter, et al.
Publicado: (2014)

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
por: Chekerov, Radoslav, et al.
Publicado: (2017)

Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients
por: Armbrust, R., et al.
Publicado: (2021)

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
por: Chekerov, Radoslav, et al.
Publicado: (2023)

Corrigendum to ‘Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients’: [ESMO Open Volume 6, Issue 2, April 2021, 100081]
por: Richter, R., et al.
Publicado: (2021)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
por: Harter, Philipp, et al.
Publicado: (2017)

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
por: Fumet, Jean-David, et al.
Publicado: (2022)

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)
por: Hauke, Jan, et al.
Publicado: (2022)

Reconstructive Surgery versus Primary Closure following Vulvar Cancer Excision: A Wide Single-Center Experience
por: Muallem, Mustafa Zelal, et al.
Publicado: (2022)

Transcriptome Analysis in Vulvar Squamous Cell Cancer
por: Prieske, Katharina, et al.
Publicado: (2021)

Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients
por: Ansorge, Nadine, et al.
Publicado: (2022)

MTA1 as negative prognostic marker in vulvar carcinoma
por: Wanka, Giulia, et al.
Publicado: (2023)

Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients
por: Ansorge, Nadine, et al.
Publicado: (2021)

A Systematic Model Specification Procedure for an Illness-Death Model without Recovery
por: Eulenburg, Christine, et al.
Publicado: (2015)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
por: Gericke, Beate, et al.
Publicado: (2005)

Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11
por: Armbrust, Robert, et al.
Publicado: (2021)

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
por: Woelber, Linn, et al.
Publicado: (2021)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis
por: Steinkasserer, L., et al.
Publicado: (2022)

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database
por: Bossart, M., et al.
Publicado: (2022)

Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Surgical Therapy for Patients with Stage IA2–IIB1 Cervical Cancer
por: Fehm, Tanja, et al.
Publicado: (2023)

Pregnancy management for a woman with extensive vulvar and pelvic malformations caused by Klippel–Trénaunay syndrome
por: Hofmann, Konstantin, et al.
Publicado: (2022)

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
por: Jaeger, A., et al.
Publicado: (2021)

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
por: Emons, Günther, et al.
Publicado: (2018)

The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group
por: Hasenburg, Annette, et al.
Publicado: (2021)

T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer
por: Burandt, Eike, et al.
Publicado: (2022)

Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
por: Emons, Günter, et al.
Publicado: (2019)

Interkulturelle Kompetenzen im Gesundheitswesen durch Fort- und Weiterbildungen fördern
por: Dimitrova, Desislava, et al.
Publicado: (2023)

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
por: du Bois, A, et al.
Publicado: (2012)

Lipid reprogramming induced by the TFEB-ERRα axis enhanced membrane fluidity to promote EC progression
por: Mao, Xiaodan, et al.
Publicado: (2022)

TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target
por: Condic, Mateja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hnqio4ep9gbgrj356l4lr5ma61